BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1810 related articles for article (PubMed ID: 26378640)

  • 1. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation.
    Younossi ZM
    Liver Transpl; 2018 Feb; 24(2):166-170. PubMed ID: 29272073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults.
    Marengo A; Jouness RI; Bugianesi E
    Clin Liver Dis; 2016 May; 20(2):313-24. PubMed ID: 27063271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude.
    Pocha C; Kolly P; Dufour JF
    Semin Liver Dis; 2015 Aug; 35(3):304-17. PubMed ID: 26378646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
    Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
    Zhu C; Zhou D; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive biomarkers in non-alcoholic steatohepatitis-induced hepatocellular carcinoma.
    Voiculescu M; Nanau RM; Neuman MG
    J Gastrointestin Liver Dis; 2014 Dec; 23(4):425-9. PubMed ID: 25532002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.
    Margini C; Dufour JF
    Liver Int; 2016 Mar; 36(3):317-24. PubMed ID: 26601627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications.
    Boutari C; Lefkos P; Athyros VG; Karagiannis A; Tziomalos K
    Curr Vasc Pharmacol; 2018; 16(3):214-218. PubMed ID: 28676025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?
    Yopp AC; Choti MA
    Dig Dis; 2015 Sep; 33(5):642-7. PubMed ID: 26398208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.
    Makri E; Goulas A; Polyzos SA
    Arch Med Res; 2021 Jan; 52(1):25-37. PubMed ID: 33334622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
    Roeb E; Geier A
    Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
    Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
    Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 91.